A detailed history of Alps Advisors Inc transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 45,536 shares of ALDX stock, worth $218,117. This represents 0.0% of its overall portfolio holdings.

Number of Shares
45,536
Previous 46,326 1.71%
Holding current value
$218,117
Previous $153,000 60.13%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$3.19 - $6.32 $2,520 - $4,992
-790 Reduced 1.71%
45,536 $245,000
Q2 2024

Aug 13, 2024

BUY
$3.25 - $4.72 $150,559 - $218,658
46,326 New
46,326 $153,000
Q3 2023

Nov 14, 2023

BUY
$6.11 - $8.16 $1,173 - $1,566
192 Added 0.45%
43,250 $288,000
Q2 2023

Aug 14, 2023

BUY
$7.11 - $11.89 $31,831 - $53,231
4,477 Added 11.6%
43,058 $361,000
Q1 2023

May 10, 2023

SELL
$5.77 - $9.93 $6,779 - $11,667
-1,175 Reduced 2.96%
38,581 $383,000
Q4 2022

Feb 14, 2023

BUY
$5.08 - $7.09 $40,350 - $56,315
7,943 Added 24.97%
39,756 $276,000
Q3 2022

Nov 14, 2022

SELL
$3.8 - $7.74 $10,518 - $21,424
-2,768 Reduced 8.0%
31,813 $170,000
Q2 2022

Aug 11, 2022

SELL
$2.43 - $4.85 $61,053 - $121,856
-25,125 Reduced 42.08%
34,581 $138,000
Q1 2022

May 16, 2022

SELL
$3.25 - $5.17 $24,430 - $38,862
-7,517 Reduced 11.18%
59,706 $265,000
Q4 2021

Feb 09, 2022

SELL
$3.5 - $9.63 $12,922 - $35,553
-3,692 Reduced 5.21%
67,223 $269,000
Q3 2021

Nov 15, 2021

SELL
$7.94 - $11.31 $39,604 - $56,414
-4,988 Reduced 6.57%
70,915 $623,000
Q2 2021

Aug 11, 2021

BUY
$10.44 - $14.85 $59,257 - $84,288
5,676 Added 8.08%
75,903 $860,000
Q1 2021

May 07, 2021

BUY
$6.53 - $14.42 $6,902 - $15,241
1,057 Added 1.53%
70,227 $834,000
Q4 2020

Feb 03, 2021

BUY
$6.31 - $8.13 $436,462 - $562,352
69,170 New
69,170 $475,000

Others Institutions Holding ALDX

About Aldeyra Therapeutics, Inc.


  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $279M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.